Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

178
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
178
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

106
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
106
Introduction to Biological Bases of Psychology01:30

Introduction to Biological Bases of Psychology

3.3K
Biopsychology serves as a vital bridge connecting the intricate domains of biology and psychology, shedding light on how biological systems influence psychological phenomena. This field scrutinizes the biological substrates of behavior and mental processes, emphasizing the nervous system along with the roles of neurotransmitters, hormones, and genetics. It also incorporates evolutionary perspectives to explain the adaptive nature of mental functions.
The nervous system, the cornerstone of...
3.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

159
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
159
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

172
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
172
T Cell Types and Functions01:24

T Cell Types and Functions

1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Vitamin D in Modulating the Innate Immune Response in Children with Vesicoureteral Reflux.

Children (Basel, Switzerland)·2026
Same author

<i>IL12B</i> rs3213094 as a Predictor of Early Response to Biologic Therapy in Psoriasis: A Real-World Study in a Romanian Cohort.

Medicina (Kaunas, Lithuania)·2026
Same author

Genetic Association Study of <i>IL23R</i> and <i>IL12B</i> Polymorphisms with Psoriasis in a Romanian Population.

Life (Basel, Switzerland)·2026
Same author

Semi-Automated Computational Identification of Fibrosis for Enhanced Histopathological Decision Support.

Journal of imaging·2026
Same author

Comparative Evaluation of Quercetin, Pioglitazone, Insulin, and Novel 5-Chromenyl-Methylene Thiazolidinedione Derivative on Nerve Function in Experimental Diabetic Peripheral Neuropathy.

Biomedicines·2026
Same author

MRI-Based Differentiation of Tumor Deposits and Lymph Node Metastases in Rectal Cancer: A Systematic Review of Diagnostic Performance.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jul 29, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients.

Teodora-Larisa Timis1, Lehel Beni2, Teodora Mocan1

  • 1Department of Physiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

Life (Basel, Switzerland)
|May 27, 2023
PubMed
Summary
This summary is machine-generated.

Biologic therapies significantly reduce psoriasis severity and improve associated depression and anxiety. All evaluated biologic agents demonstrated efficacy, with no single agent proving superior for these outcomes.

Keywords:
DLQIPASIanxietybiologic agentsdepressionpsoriasisseverity

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

436
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

820

Related Experiment Videos

Last Updated: Jul 29, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

436
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

820

Area of Science:

  • Dermatology
  • Psychiatry
  • Immunology

Background:

  • Psoriasis is a chronic, immune-mediated skin disease with substantial psychological impact.
  • Biologic agents represent a newer therapeutic option for managing psoriasis.
  • Psychological comorbidities like depression and anxiety are prevalent in psoriasis patients.

Purpose of the Study:

  • To evaluate the efficacy of biologic therapies in treating psoriasis.
  • To assess the impact of biologics on disease severity and psychological comorbidities.
  • To compare the prevalence of depression and anxiety in psoriasis patients versus controls.

Main Methods:

  • Prospective case-control study comparing 106 psoriasis patients with 106 controls.
  • Assessment of depression (PHQ-9) and anxiety (GAD-7) scores at baseline and 6 months.
  • Evaluation of Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores.
  • Treatment with one of seven biologic agents: ixekizumab, secukinumab, guselkumab, certolizumab, ustekinumab, risankizumab, or adalimumab.

Main Results:

  • Psoriasis patients exhibited significantly higher rates of depression and anxiety (p < 0.0001).
  • Female patients reported higher depression and anxiety prevalence in both groups.
  • Biologic therapy led to significant reductions in PASI, DLQI, PHQ-9, and GAD-7 scores (p < 0.0001) at 6 months.
  • Improved PASI scores correlated with reduced depression and anxiety (p < 0.005), but DLQI did not.

Conclusions:

  • Biologic therapies are effective in managing psoriasis severity.
  • Biologics significantly alleviate depression and anxiety symptoms in patients with psoriasis.
  • No specific biologic agent demonstrated superiority among the seven studied agents.